RNAZ

#4286
TransCode Therapeutics, Inc. - Common Stock
2.8 7 USD
0.00%
Market Price
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
2.65
2.90
Year Range
2.65
10.69
Daily Change
0.00%
Monthly Change
-51.27%
6 month change
-70.17%
Year Change
-69.82%
Previous Close
2.8 7
Open
2.8 8
Low
2.6 5
High
2.9 0
Volume
19
Open full chart

Financials

Overview Statement Statistics Documents

2026

Current report, Q3 FY2026
Transcode Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Transcode Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Transcode Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Transcode Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Transcode Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Transcode Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Transcode Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Transcode Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Transcode Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Transcode Therapeutics, Inc. current report, Q2 FY2026
8-K

Transcode Therapeutics, Inc. current report, Q4 FY2024

Full document

Transcode Therapeutics, Inc. (RNAZ) - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed on November 26, 2024, by Transcode Therapeutics, Inc., a Delaware corporation and emerging growth company. The report details a material corporate action approved by stockholders on November 22, 2024, and filed with the State of Delaware on November 26, 2024.

Key Financial Metrics

This filing does not contain financial performance data such as revenue, profit, cash flow, margins, or debt levels. The report focuses exclusively on a capital structure adjustment. Post-transaction, the company expects to have approximately 696,233 shares of Common Stock issued and outstanding, following the reverse split and a previously announced private placement.

Material Changes

  • Reverse Stock Split: The Company effected a 1-for-33 reverse stock split of its issued and outstanding common stock.
  • Effective Date: The split became effective at 12:01 a.m. Eastern Time on December 4, 2024.
  • Trading Details: Trading on the Nasdaq Capital Market resumed on December 4, 2024, on a split-adjusted basis under the symbol RNAZ with a new CUSIP number (89357L 402).
  • Adjustments: Outstanding stock options and warrants were proportionally adjusted for share count and exercise prices. The par value per share remains unchanged at $0.0001.
  • Fractional Shares: Fractional shares resulting from the split are rounded up to the nearest whole number rather than being issued or cashed out.

Guidance, Outlook, and Risks

The filing does not provide forward-looking financial guidance, management commentary on operational outlook, or specific risk factors beyond the standard disclosure regarding the reverse split mechanics. The primary purpose of the filing is to disclose the amendment to the Certificate of Incorporation and the resulting change in the rights of security holders.

Investor Verification Checklist

  • Verify the new CUSIP number (89357L 402) for trading purposes starting December 4, 2024.
  • Confirm the adjusted share count and exercise prices for any held stock options or warrants.
  • Contact brokerage firms to ensure fractional share rounding procedures are correctly applied to street-name holdings.
  • Review the full text of the Certificate of Amendment (Exhibit 3.1) for complete legal terms.

News